Showing results (411-420 of 513) with videos related to

Sort By:
Pageof 52
Anticancer Research|July 1, 1997
Transient exposure to cytarabine increases peptide growth factor receptor expression and tumorigenicity of melanoma cellsM Caraglia, A I Leardi, S Improta, et al.
Oncogene|September 22, 1999
Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor geneB Belletti, P Ferraro, C Arra, et al.
Surgery|June 6, 2021
Natural language processing for the surveillance of postoperative venous thromboembolismJianlin Shi, John F Hurdle, Stacy A Johnson, et al.
ACR Open Rheumatology|February 28, 2024
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
Dermatology and Therapy|February 15, 2022
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17April W Armstrong, Andrew Blauvelt, Ulrich Mrowietz, et al.
Dermatology and Therapy|January 21, 2021
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis RegistryAlice B Gottlieb, Joseph F Merola, Joshua Cirulli, et al.
ACS Applied Materials & Interfaces|April 21, 2018
Pyroelectric Effect Enables Simple and Rapid Evaluation of Biofilm FormationO Gennari, V Marchesano, R Rega, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Patient Preference and Adherence|July 2, 2020
Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country StudyDaniel Aletaha, M Elaine Husni, Joseph F Merola, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Pageof 52